Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) As a result of cost-cutting initiatives resulting from the recent clinical failure of Sulonex (sulodexide), Keryx Biopharmaceuticals, Inc. (the "Company") and its Chief Accounting Officer, Mark Stier, have mutually agreed that Mr. Stier will resign from the Company effective June 30, 2008.

---